文章基本信息

标题：Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare
本地全文：下载
作者：Robert I. Griffiths ; Michelle L. Gleeson ; Joseph Mikhael 等
期刊名称：Journal of Cancer Epidemiology
印刷版ISSN：1687-8558
电子版ISSN：1687-8566
出版年度：2012
卷号：2012
DOI：10.1155/2012/978391
出版社：Hindawi Publishing Corporation
摘要：Rituximab improves survival in follicular lymphoma (FL), but is considerably more expensive than conventional chemotherapy. We estimated the total direct medical costs, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for FL, based on a single source of data representing routine practice in the elderly. Using surveillance, epidemiology, and end results (SEER) registry data plus Medicare claims, we identified 1,117 FL patients who received first-line CHOP (cyclophosphamide (C), doxorubicin, vincristine (V), and prednisone (P)) or CVP